Alexium receives US EPA approval for Alexiflam® NF
Alexium International Group Ltd (ASX:AJX, NASDAQ:AXXIY) has received US Environmental Protection Agency (EPA) approval under TSCA (Toxic Substance Control Act) for the manufacture and sale of Alexiflam® NF in the US.
The EPA approval provides Alexium with access to the largest market region for flame retardant cotton and follows the recently negotiated Memorandum of Understanding with ICL (TASE/NYSE: ICL) for the future manufacture, marketing and sales of Alexiflam® NF.
Alexiflam® NF is a patent pending flame retardant developed by Alexium for the treatment of cotton and cellulose-based textiles.
Alexiflam® NF has enhanced flame-retardant properties over incumbent products, and it also provides a number of improved environmental and health advantages.
These include the product being essentially formaldehyde free, as well as featuring an ammoniation free application.
Alexium to meet military and industrial sales targets
The approval received under the US Toxic Substances Control Act (TSCA) follows the successful completion of the EPA’s risk assessment of the hazards associated with the manufacturing, processing, and use of Alexiflam® NF.
TSCA regulates the introduction of new chemical products in the US, and its stringent expectations work in favour of Alexium, effectively providing reasonable barriers to entry in relation to potential competitors.
Recently updated by the Lautenberg Chemical Safety Act, the assessment of Alexiflam® NF was under the more rigorous new TSCA standard.
This EPA approval provides Alexium with the ability to manufacture and sell Alexiflam® NF in the US, which represents nearly half of the global flame-retardant cotton market.
Based on the provisions of the approval, Alexium can produce the volumes of Alexiflam® NF needed to support the company’s sales targets for military and industrial application in the US.
Alexium can now focus on commercialisation
Commenting on the EPA’s approval of Alexiflam NF®, Alexium chief executive Bob Brookins said, “EPA approval of Alexiflam® NF marks a significant milestone for the company.
“This approval supports Alexium’s manufacture and sales into the US, which represents the largest global market for flame retardant cotton products.
“The EPA approval builds on our recent MoU with ICL for them to act as the future manufacturer and distributor of Alexiflam® NF.”
The prior consolidation of the arrangement with ICL makes this development all the more significant as it leaves Alexium well placed to drive the commercialisation of Alexiflam® NF, delivering on the extensive global sales opportunities for the unique textile technology.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.